Docoh
Loading...

CYTK Cytokinetics

Employees

Data from SEC filings
Employee count

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM


The following is a brief description of each matter voted upon at the Company’s Annual Meeting of Stockholders on May 12, 2021 (the “Annual Meeting”), as well as the number of votes cast for or against each matter and the number of abstentions and broker non-votes with respect to each matter. Of the 71,536,632 shares of the Company’s common stock entitled to vote at the Annual Meeting, 63,410,394 shares of common stock, or 88.64%, of the total eligible votes to be cast, were represented at the Annual Meeting in person or by proxy, constituting a quorum. A more complete description of each matter is set forth in the Company’s definitive proxy statement for the Annual Meeting, which was filed with the Securities and Exchange Commission on April 7, 2021.

Proposal 1: Election of Three Class II Directors

The stockholders elected Robert I. Blum, Robert M. Califf, M.D., and Sandford D. Smith as Class II Directors, each to serve for a three-year term and until their successors are duly elected and qualified or their earlier resignation or removal. The voting for each director was as follows:

Name For Withheld Broker

Non-Vote
Robert I. Blum58,171,626480,1004,758,668
Robert M. Califf, M.D.58,473,677178,0494,758,668
Sandford D. Smith57,167,9491,483,7774,758,668


Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2004 Equity Incentive Plan to increase the number of authorized shares reserved for issuance under Amended and Restated 2004 Equity Incentive Plan by 5,219,000 shares of common stock.



The stockholders approved the amendment and restatement of the Amended and Restated 2004 Equity Incentive Plan to increase the number of authorized shares reserved for issuance under the Amended and Restated 2004 Equity Incentive Plan by an additional 5,219,000 shares of common stock. The votes were as follows:

For Against Abstain Broker Non-Vote
54,360,9234,138,734152,0684,758,668




Proposal 3: Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2021



The stockholders ratified the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. The votes were as follows:

For Against Abstain Broker Non-Vote
63,223,99111,072175,330-0-




Proposal 4: Advisory Vote on Executive Compensation



The stockholders approved, on an advisory basis, the compensation of the named executive officers, as disclosed in the Company’s Proxy Statement for the 2021 Annual Meeting of Stockholders. The votes were as follows:

For Against Abstain Broker Non-Vote
55,993,2322,372,911285,5824,758,668